Introduction
In addition to established risk factors such as hepatitis and alcohol consumption, obesity and its related metabolic abnormalities raise the risk of hepatocellular carcinoma (HCC) (1) (2) (3) (4) . Several pathophysiological mechanisms linking obesity and liver carcinogenesis have been demonstrated, including the emergence of insulin resistance and the subsequent inflammatory cascade (5) . In obese individuals, increased adipose tissue leads to the expression of a variety of adipocytokines. Recently, the role of obesity-associated dysfunctional adipose tissue and subsequent adipocytokine dysbalance in carcinogenesis has attracted attention (6) . Clinical trials have shown that adipocytokine disorders, including increased levels of leptin and decreased levels of adiponectin in the serum, are implicated in hepatocarcinogenesis (7, 8) . Leptin induces proliferation and inhibits apoptosis in human HCC cells (9) . These findings suggest that adipocytokine dysbalance may play an important role in the development and progression of HCC.
Visfatin/pre-B cell enhancing factor, which was originally isolated from peripheral lymphocytes, has been described as a secreted growth factor for early B cell proliferation (10) . More recently, visfatin has also been characterized as an adipocytokine that is highly expressed in the visceral fat of humans and rodents.
Increased levels of visfatin, which are positively correlated with the size of visceral fat deposits, are observed in various clinical conditions such as obesity and diabetes mellitus (11, 12) . Abnormalities in serum levels of visfatin have also been reported in nonalcoholic fatty liver disease (NAFLD), which is a hepatic manifestation of metabolic syndrome (13) . These results are somewhat conflicting, however, as both increased and decreased serum levels of this adipocytokine have been found in patients with NAFLD (14, 15) . Furthermore, previous studies have shown that visfatin may play a role in the development and progression of certain types of human malignancies (16) . For instance, colorectal cancer, the development of which is associated with metabolic abnormalities (17) , is accompanied by the overexpression of visfatin (18) . Serum visfatin level is a good biomarker of colorectal malignant potential and stage progression (19) . Visfatin stimulation increases cell proliferation in prostate and breast cancer cells (20, 21) , whereas the use of visfatin inhibitor exerts an anti-tumor effect by inducing apoptosis (22) . These findings suggest that visfatin is one of the key adipocytokines that links obesity and tumorigenesis and thus may be an effective target for the inhibition of obesity-related carcinogenesis. However, no detailed studies of the relationship between visfatin and HCC have yet been conducted.
Branched-chain amino acids (BCAA; leucine, isoleucine, and valine) is used in patients with liver cirrhosis to improve protein malnutrition (23) . Recent clinical trials have demonstrated that oral supplementation with BCAA prevents progressive hepatic failure, improves event-free survival in patients with chronic liver diseases, and reduces the risk of HCC in these patients who are obese (BMI of 25 or higher) (4, 24) . BCAA supplementation also prevents obesity-related carcinogenesis in both the liver and the colorectum of diabetic mice (25, 26) . In the present study, we measured serum visfatin concentration in patients with HCC and examined whether it was correlated with stage progression and tumor enlargement. We also examined in detail the effects of visfatin on the acceleration of HCC cell proliferation, focusing on the activation of signaling pathways, and investigated whether BCAA suppresses visfatin-induced growth of HCC cells.
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Materials and methods

Patients and measurement of serum visfatin concentration
Eighty-five primary HCC patients who underwent initial treatment at our hospital from January 2006 to December 2008 were enrolled in this study. Tumor stage was defined according to the staging system of the Liver Cancer Study Group of Japan (27) . The greatest diameter of HCC was determined using dynamic CT or MRI.
Fasting serum samples were collected at the time of diagnosis, and serum levels of visfatin were determined using ELISA (AdipoGen, San Diego, CA, USA). The study protocol was approved by the institutional review board for human research, and all patients gave written informed consents to enter the study. 
Materials
Protein extraction and Western blot analysis
Total cellular protein was extracted and equivalent amounts of protein were examined by Western blot analysis (28) . The primary antibodies used to detect the respective protein bands have been described previously (28) . An antibody to GAPDH was used as a loading control. The intensities of the blots were quantified with NIH Image software, version 1.62.
Cell cycle assays
Cell cycle assays were performed using a cell cycle detection kit (Cayman, Ann Arbor, MI, USA) according to the manufacturer's instructions. HepG2 cells were treated with BCAA for 48 hours in the absence and presence of 100 ng/mL visfatin.
After the harvested cells were fixed and stained, they were analyzed for DNA histograms and cell cycle phase distribution using a FACScan flow cytometer (BD, Franklin Lakes, NJ, USA). The data were analyzed by using the CellQuest computer program (BD) as described previously (28) .
Apoptosis assays
The previously (29) .
Statistical analysis
The data are expressed as mean ± SD. The statistical significance of the difference in mean values was assessed with one-way ANOVA, followed by Sheffe's t-test. Values of P < 0.05 were considered significant. 
Effects of visfatin on cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in human HCC cells
We next examined whether visfatin stimulates the proliferation of HCC cells using XTT assay. When series of HCC cells (i.e., HepG2, Hep3B, and HuH7 cells) were treated with visfatin (25 to 400 ng/mL) for 48 hours, cell proliferation was significantly stimulated in a dose-dependent manner (P < 0.05; Figs. 2A, 2B, and 2C ).
In addition, treatment of HepG2 cells with 100 ng/mL of visfatin for 30 minutes caused a marked phosphorylation of ERK, Akt, and GSK-3β proteins (Fig. 2D) 
MAPK/ERK signaling pathways.
Effects of PI3K, MEK1, and GSK-3β inhibitors on visfatin-induced proliferation of
HepG2 cells
We next examined whether pharmacologic inhibitors of PI3K (LY294002), MEK1 (PD98059), and GSK-3β (CHIR99021) suppress visfatin-induced proliferation in HepG2 cells because the activation of PI3K/Akt and MAPK/ERK pathways might be involved in this proliferation (Fig. 2) . As shown in Fig. 3 , treatment with LY294002 (Fig. 3A) , PD98059 (Fig. 3B) , and CHIR99021 (Fig. 3C ) significantly inhibited HepG2 cell proliferation both in the absence and presence of visfatin stimulation (100 and 400 ng/mL) (P < 0.05). These findings suggest that PI3K and MAPK pathways could be effective targets for the inhibition of visfatin-induced proliferation in HepG2 cells.
Effects of BCAA on visfatin-induced proliferation of HepG2 cells
BCAA is reported to suppress obesity-related liver carcinogenesis (4, 25) . Therefore, we next examined whether BCAA inhibits visfatin-stimulated proliferation of HepG2 cells because this adipocytokine, which is increased in obese individuals (11, 12) , might play a role in the progression of HCC (Fig. 1) . As shown in visfatin stimulation (P < 0.05). The inhibition of proliferation with 2 mM BCAA was greater (65% reduction) when the cells were cultured at higher concentration of visfatin (400 ng/mL) than that in the absence of the adipocytokine (41% reduction) (Fig. 4B) .
In contrast, cell proliferation was not induced when Hc normal hepatocytes were treated with similar concentrations of visfatin. BCAA also exerted no significant effect on the proliferation of Hc cells regardless of visfatin stimulation (Fig. 4C) .
Effects of BCAA on visfatin-induced phosphorylation of ERK, Akt, and GSK-3β proteins in HepG2 cells
We next examined whether BCAA affected the phosphorylation of ERK, Akt, and GSK-3β proteins caused by visfatin in HepG2 cells. When the cells were stimulated by visfatin, the expression levels of p-GSK-3β protein were significantly decreased by BCAA treatment (P < 0.05; 
Discussion
Obesity and related metabolic abnormalities are significant risk factors for the development of HCC (1) (2) (3) (4) (5) . Among obesity-related metabolic disorders, adipocytokine dysbalance is considered to play a role in liver carcinogenesis (7-9); however, the detailed relationship remains unclear. The results of the present study provide the first evidence that higher levels of serum visfatin, which are frequently found in obese individuals (11, 12) -11-0340 in these cells. These findings are consistent with previous reports that visfatin regulates a variety of signaling pathways, including PI3K/Akt, MAPK/ERK, and Stat3 (20, 32, 33) . Visfatin stimulation also increases cell proliferation and ERK activity in prostate cancer cells (20) . Moreover, recent experimental studies have shown that the activation of PI3K/Akt, MAPK/ERK, and Stat3 pathways is significantly associated with the development of liver tumors in obese mice and that inhibiting the activation of these signaling pathways is critical to the prevention of obesity-related liver tumorigenesis (34, 35) . These reports (34, 35) , together with the present findings that specific inhibitors of PI3K, MEK1, and GSK-3β significantly suppress visfatin-induced proliferation in HCC cells suggest that visfatin and its related signaling pathways might be effective targets for inhibiting obesity-related liver carcinogenesis.
BCAA, which was originally developed to improve protein malnutrition in patients with liver cirrhosis (23), produces improvements in metabolic abnormalities, especially insulin resistance and glucose tolerance (36, 37) . BCAA supplementation also reduces the weights of white adipose tissue and improves liver steatosis in mice fed a high-fat diet (38) . In addition, long-term oral supplementation with BCAA is associated with a reduced frequency of HCC in obese individuals (4) . In rodent models, BCAA prevents obesity-related liver and colorectal carcinogenesis, and their beneficial effects are involved in the amelioration of insulin resistance and reduction of serum leptin levels (25, 26, 39) . In the present study, BCAA significantly inhibited the proliferation of HCC cells stimulated by visfatin without affecting that of normal hepatocytes. This mechanism is a new one of BCAA that might explain the suppressive effects of this agent on obesity-related tumorigenesis. Therefore, the evidences in the present and previous studies (4, 25, 39) 
